Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas

SIMPLE SUMMARY: Currently, as a neoadjuvant conversion therapy (NCT), pazopanib combined with neoadjuvant chemoradiotherapy could improve the pathological response of unresectable soft tissue sarcoma (uSTS). However, there is no available evidence of its effectiveness with respect to tumor reduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Zuoyao, Lu, Yajie, Li, Minghui, Fu, Zhanli, Akbar, Yunus, Li, Jing, Chen, Guojing, Zhang, Hong-Mei, Wang, Qi, Xiang, Liangbi, Wang, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913396/
https://www.ncbi.nlm.nih.gov/pubmed/36765658
http://dx.doi.org/10.3390/cancers15030700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913396/
https://www.ncbi.nlm.nih.gov/pubmed/36765658
http://dx.doi.org/10.3390/cancers15030700

Ejemplares similares